Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Revenue (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Revenue for 4 consecutive years, with $57.6 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 94.12% to $57.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $175.1 million through Dec 2025, up 216.93% year-over-year, with the annual reading at $175.1 million for FY2025, 216.93% up from the prior year.
  • Revenue for Q4 2025 was $57.6 million at Phathom Pharmaceuticals, up from $49.5 million in the prior quarter.
  • The five-year high for Revenue was $57.6 million in Q4 2025, with the low at -$9.6 million in Q4 2022.
  • Average Revenue over 4 years is $15.7 million, with a median of $7.3 million recorded in 2024.
  • The sharpest move saw Revenue surged 4249.56% in 2024, then skyrocketed 94.12% in 2025.
  • Over 4 years, Revenue stood at -$9.6 million in 2022, then surged by 107.1% to $682000.0 in 2023, then soared by 4249.56% to $29.7 million in 2024, then skyrocketed by 94.12% to $57.6 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $57.6 million, $49.5 million, and $39.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.